Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Denali Therapeutics Inc. (DNLI) had Normalized Income after Taxes of $-126.90M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-126.90M |
|
-- |
|
-- |
|
$137.43M |
|
$-137.43M |
|
$10.53M |
|
$-126.90M |
|
$-126.90M |
|
$-126.90M |
|
$-126.90M |
|
$-126.90M |
|
|
Normalized Income after Taxes |
$-126.90M |
$-137.43M |
|
$-136.51M |
|
172.42M |
|
172.42M |
|
$-0.74 |
|
$-0.74 |
|
| Balance Sheet Financials | |
$882.60M |
|
$53.73M |
|
$173.02M |
|
$1.06B |
|
$90.15M |
|
$5.55M |
|
$39.28M |
|
$129.42M |
|
$926.20M |
|
$926.20M |
|
$926.20M |
|
146.63M |
|
| Cash Flow Statement Financials | |
$-314.06M |
|
$234.51M |
|
$-2.92M |
|
$176.53M |
|
$94.07M |
|
$-82.47M |
|
$75.68M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.79 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-322.04M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.70% |
|
-13.70% |
|
-12.02% |
|
-13.62% |
|
$6.32 |
|
$-1.87 |
|
$-1.82 |
|